Inhibition of lactation: risks associated with dopamine agonists.

The 31st French Pharmacovigilance Meeting took place in March 2010 in Bordeaux. Each year this conference examines adverse events reported to regional pharmacovigilance centres by healthcare professionals, as well as the French pharmacovigilance database. The following articles will examine presentations having important practical implications, which provide useful feedback and encourage further reporting. These presentations highlight the importance of reporting adverse effects, and their analysis by pharmacovigilance centres independent of the pharmaceutical industry, in providing transparent, high-quality information that serves patients’ best interests. 31st French Pharmacovigilance Meeting: selected presentations